EuroAPI is pausing all production at its site in Brindisi, Italy, causing Sanofi’s API spinoff to delay its 2024 guidance until the second quarter.
“Following an internal audit, quality control deficiencies due to potential local misconduct have been identified and are being further investigated,” the company said in a Thursday release. “Production will remain suspended until further notice. The relevant health authorities have been informed. The company has initiated a forensic audit and will inform its customers.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.